Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib
To access this article, please choose from the options below
PII: S0959-8049(06)00803-3
doi:10.1016/j.ejca.2006.08.032
© 2006 Elsevier Ltd. All rights reserved.
